Get the Stockscreener App
295.05
0.29%
-0.86
Alnylam Pharmaceuticals Inc stock is traded at $295.05, with a volume of 926.34K.
It is down -0.29% in the last 24 hours and down -9.84% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
See More
Previous Close:
$295.91
Open:
$295.91
24h Volume:
926.34K
Relative Volume:
0.76
Market Cap:
$39.39B
Revenue:
$4.29B
Net Income/Loss:
$577.22M
P/E Ratio:
70.11
EPS:
4.2086
Net Cash Flow:
$641.34M
1W Performance:
-0.36%
1M Performance:
-9.84%
6M Performance:
-33.35%
1Y Performance:
+14.21%
1-Day Range:
$293.06
$300.17
1-Week Range:
$288.06
$306.03
52-Week Range:
$250.35
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-07-26 | Resumed | Oppenheimer | Outperform |
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - Yahoo Finance
Is It Time To Reconsider Alnylam Pharmaceuticals (ALNY) After Recent RNAi Progress And Volatile Price Moves - simplywall.st
Heart drug vutrisiran shows steady profile in new analyses - Longevity.Technology
FDA’s Untitled Letter tells Alnylam its Amvuttra survival claims don’t quite add up - Medical Marketing and Media
Porphyria Treatment Market to Reach USD 2.56 Billion by 2033 - openPR.com
Alnylam to Webcast Presentations at Upcoming Investor Conferences - Yahoo Finance
Tenaya (NASDAQ: TNYA) trims R&D burn and signs Alnylam research pact - Stock Titan
Tenaya Therapeutics (NASDAQ: TNYA) trims Q1 loss, lands Alnylam deal - Stock Titan
Alnylam Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
FMR LLC amends Schedule 13G to show 14.64M ALNY shares (NASDAQ: ALNY) - Stock Titan
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
H.C. Wainwright reiterates Alnylam stock rating on strong TTR sales By Investing.com - Investing.com Canada
Competitive Landscape: Leading Companies and Emerging Competitors in the Vutrisiran Market - openPR.com
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Alnylam Pharmaceuticals (ALNY) Valuation After Q1 2026 Profit Breakthrough And Revenue Surge - simplywall.st
MSN Money - MSN
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $429 - Moomoo
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM - Business Wire
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Navigating a 51.79% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Alnylam Pharmaceuticals Q1 2026 earnings preview - MSN
Should Alnylam’s Billion‑Dollar Quarter and Return to Profitability Require Action From Alnylam Pharmaceuticals (ALNY) Investors? - simplywall.st
Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Hussman Strategic Advisors Inc. Buys Shares of 6,300 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Kornitzer Capital Management Inc. KS - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Danske Bank A S - MarketBeat
Alnylam Pharmaceuticals (ALNY) Financials 2026Income Statement and Balance Sheet - MarketBeat
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $370 to $500 - Moomoo
Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY) - The Globe and Mail
Alnylam Pharma (ALNY) Gets a Buy from Bernstein - The Globe and Mail
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Wall Street Zen - MarketBeat
Alnylam slips 4.3% as investors digest Q1 results and unchanged full-year outlook - Quiver Quantitative
ALNY Maintained by RBC Capital -- Price Target Lowered to $445 - GuruFocus
ALNY Maintained by Wells Fargo -- Price Target Raised to $377 - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year - Seeking Alpha
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth - Yahoo Finance
Bernstein SocGen lowers Alnylam stock price target on valuation By Investing.com - Investing.com Canada
Bernstein SocGen lowers Alnylam stock price target on valuation - Investing.com
Wells Fargo & Company Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $445 - Moomoo
RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating - marketscreener.com
Alnylam Pharmaceuticals Backs 2026 Views >ALNY - Moomoo
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Jennison Associates LLC - MarketBeat
Alnylam Pharmaceuticals Inc (ALNY) Q1 2026 Earnings Call Highlig - GuruFocus
Alnylam Pharmaceuticals (ALNY) Earnings Turn To Profitability Challenges Premium P/E Narrative - simplywall.st
Congress Large Cap Growth Fund's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2026 Earnings Call Transcript - Insider Monkey
ALNY SWOT Analysis: Strong Growth Potential Revealed in 10-Q Fil - GuruFocus
Alnylam Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ALNY) 2026-04-30 - Seeking Alpha
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $482 - Moomoo
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 02 '26 |
Sale |
319.59 |
1,624 |
519,014 |
11,729 |
1.54%
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):